| Assessment Status |
Awaiting full HTA submission from Applicant |
| HTA ID |
23064 |
| Drug |
Tebentafusp |
| Brand |
Kimmtrak® |
| Indication |
Tebentafusp is indicated as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. |
| Rapid review commissioned |
10/10/2023 |
| Rapid review completed |
13/11/2023 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tebentafusp compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
29/11/2023 |
| Pre-submission consultation with Applicant |
11/02/2025 |
